Press Releases

Switzerland based Tenthpin Management Consultants, a global leader in management and technology consulting for Life Sciences companies has announced the launch of Innovation Hub in Bengaluru, establishing a Global Centre of Excellence dedicated to advanced therapies that delivers a cutting-edge AI and cloud-driven solutions that help organizations accelerate and transform complex gene, cell, and tissue treatments into life-saving medicines. By bringing together deep scientific exper

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreen™ platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes

Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data. Ginkgo Datapoints will provide discovery data generation services, including small molecule dev

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. "ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy," said Renee Gala, president and chief executive officer of Jazz

ChargePoint Technology has announced the launch of ChargePoint Actis™, a breakthrough aseptic transfer system set to fundamentally change how pharmaceutical manufacturers achieve sterility assurance at one of the most critical risk points of aseptic processes. For the first time, ChargePoint Actis™ enables isolator-level regulatory confidence in a single compact system. As a result, it has the potential to transform Annex 1-aligned facility design, reduce infrastructure costs and

BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing potentially curative therapies for advanced cancers — today announced AIFA approval of a first-in-kind cGMP manufacturing line for ML-016, the company’s lead clinical-stage cancer therapeutic. AIFA is the national public body that regulates medicines for human use in Italy, where BrYet’s manufacturing subsidiary is located. The milestone clears an important manufacturing an

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT. The designation was supported by the significant unmet medical need in MDD and results from the Company&

The Parenteral Drug Association (PDA) Asia Pacific will host the PDA Aseptic Processing of Biopharmaceuticals Conference 2026 on 3-4 November 2026 at the Sheraton Grand Incheon Hotel in Incheon, South Korea. As sterile manufacturers respond to evolving regulatory expectations and increasingly complex biopharmaceutical products, the conference will examine how organizations can strengthen contamination control, protect product quality, and build more resilient aseptic manufacturing o

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®; generic name: lecanemab) as an initiation treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD dementia (collectively referred to as early AD). Th

HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an investigational antibody-targeted therapy conjugate (ATTC) designed to target KRAS and EGFR in solid tumours. EGFR is an established driver of tumour growth in several solid cancers, including colorectal, pancreatic and non-small-cell lung cancers. It also plays an important role in resistance to KRAS-targeted treatments, particularly in colorectal cancer. Targeting both EGFR and KR